馬場 英 ばば まさる 先生

来歴等

略歴

2003年 弘前大学医学部 卒業
2003年 北海道大学附属病院 第一内科
2005年 北海道社会保険病院 消化器科
2014年 独立行政法人地域医療機能推進機構北海道病院 消化器内科
2021年 独立行政法人地域医療機能推進機構北海道病院 消化器内科 医長

論文

• 1. Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness. BMC gastroenterology 2011 11:70

• 2. Serum angiopoietin-2 predicts the occurrence and recurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C. Viruses 2023 Jan7;15(1):181.doi:10.3390/v15010181

• 3. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis. J Med Virol.2023Feb;95(2):e28452

• 4. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.Sci Rep.2022Oct7;12(1):16800

• 5. Early and effect on liver functional reserve of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet eligibility criteria of IMblabe150. Cancers.2022Aug15;14(16):3938

• 6. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment. Liver Cancer 2022 Oct31;12(2):156-170

• 7. Comparison of liver scintigraphy and the liver-spleen contrast in Gd-EOB-DTPA-enhanced MRI on liver function tests. Sci Rep.2021 Nov 18;11:22472

• 8. Prediction of hepatocellular carcinomausing age and liver stiffness on transient elastography after hepatitis C virus eradication. Sci Rep.2022 Jan 27;12(1)1449

• 9. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021 Mar;56(3):261-273

• 10. Early response and safety of atezolizumab plus bevasizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res. 2021 Sep;51(9):979-989

• 11. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatotos B virus infection. J Gastroenterol.2021 Feb;(56):168-180

• 12. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One. 2021 Mar1;16(3):e0247728

受賞

• 日本消化器病学会奨励賞（第106回日本消化器病学会北海道支部例会）｢NASH症例におけるLosartan,Pioglitazone使用による治療効果-病理学的パラメータと各種検査所見の推移-｣